US Stem Cell Inc (OTCMKTS:USRM) has been struggling of late after a very strong start to the year. But USRM caught a 34% bounce on Friday. It’s important to remember that this stock was sitting at $0.0025 back in January. In other words, US Stem Cell is still up over 850% just in 2017. That said, by the same token, we are also talking about a stock that is down from $0.15 to $0.024 in just over 4 months.
The company’s latest release offers some insight into the current focus of management as operations roll forward. To wit: the company just announced “historic results from operations for the quarter ending June 30, 2017.” “We continue to see improvements in operations and balance sheet performance, specifically in the year-over-year increase in both revenue and profit,” said Mike Tomás, President & CEO of U.S. Stem Cell, Inc. “These positive results can be attributed to growing top line revenues through the expansion of our clinics, clinic partnerships, banking patients’ stem cells for future usage, training physicians, and pursuing new international business opportunities for growth.”
US Stem Cell Inc (OTCMKTS:USRM) bills itself as a company committed to the development of effective cell technologies to treat a variety of diseases and injuries. By harnessing the body’s own healing potential, we may be able to reverse damaged tissue to normal function.
The company’s discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
USRM is focused on regenerative medicine. While most stem cell companies use one particular cell type to treat a variety of diseases, U.S Stem Cell utilizes various cell types to treat different diseases. It is our belief that the unique qualities within the various cell types make them more advantageous to treat a particular disease.
According to company materials, “USRM is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.”
Find out when $USRM reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, USRM investors have fallen on hard times in recent months. The company just reported some stand-out financial data, but the stock has not responded well, suggesting that there are larger issues going on for the company in the market’s mind.
According to the release, the company reports the following results: revenue up by 104% year-over-year for the quarter: from $678K in Q2 2016 to 1.38M in Q2 2017. Revenue up by 83% YTD: from $1.39M this time last year to $2.54M in Q2 2017. Margin increased from 65% to 71% quarter-to-quarter. Gross profit up by 122% (or $542K) year-over-year for the quarter: from $442K in Q2 2016 to $985K in Q2 2017. Gross profit up by 80% (or $796K) YTD: from $999K this time last year to $1.79M in Q2 2017. Income from operations increased from a loss of ($259K) in Q2 2016 to a gain of $142K in Q2 2017, a three-month comparison. Income from operations increased YTD from a loss of ($272K) in Q2 2016 to a gain of $100K in Q2 2017, a six-month comparison. Cash Flow is positive YTD at Q2 2017 at $785K compared to YTD Q2 2016 at ($165K), a six-month comparison. In addition, working Capital Deficit down 6.9% from $5.8M in Q2 2016 to $5.4M in Q2 2017.
It’s important to note that this is no pink sheet name. And these are audited results. That makes it all the more interesting that the market has dropped the ticker over 30% on the back of these reported results.
We’ve witnessed above -40% stripped out of share pricing for the stock in the past week. That said, the situation may be worth watching. USRM has a track record that includes a number of dramatic bounces. In addition, the listing has seen interest climb, with an increase in recent trading volume of 18% beyond its prior sustained average level.
At this time, carrying a capital value in the market of $10.1M, USRM has a bankroll ($930K) of cash on the books, which must be weighed relative to about $2.9M in total current liabilities. USRM is pulling in trailing 12-month revenues of $4.2M. In addition, the company is seeing major top line growth, with y/y quarterly revenues growing at 104.3%. We will update the story again soon as developments transpire. For continuing coverage on shares of $USRM stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next breakout pick!
Disclosure: We hold no position in $USRM, either long or short, and we have not been compensated for this article.